DAB2

Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)

PDB rendering based on 1m7e.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols DAB2 ; DOC-2; DOC2
External IDs OMIM: 601236 MGI: 109175 HomoloGene: 1026 GeneCards: DAB2 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 1601 13132
Ensembl ENSG00000153071 ENSMUSG00000022150
UniProt P98082 P98078
RefSeq (mRNA) NM_001244871 NM_001008702
RefSeq (protein) NP_001231800 NP_001008702
Location (UCSC) Chr 5:
39.37 – 39.46 Mb
Chr 15:
6.3 – 6.44 Mb
PubMed search

Disabled homolog 2 is a protein that in humans is encoded by the DAB2 gene.[1][2]

Function

DAB2 mRNA is expressed in normal ovarian epithelial cells but is down-regulated or absent from ovarian carcinoma cell lines. The 770-amino acid predicted protein has an overall 83% identity with the mouse p96 protein, a putative mitogen-responsive phosphoprotein; homology is strongest in the amino-terminal end of the protein in a region corresponding to the phosphotyrosine interaction domain. The down-regulation of DAB2 may play an important role in ovarian carcinogenesis. This gene was initially named DOC2 (for Differentially expressed in Ovarian Cancer) and is distinct from the DOC2A and DOC2B genes (for double C2-like domains, alpha and beta).[3]

Interactions

DAB2 has been shown to interact with:

References

  1. Albertsen HM, Smith SA, Melis R, Williams B, Holik P, Stevens J, White R (January 1997). "Sequence, genomic structure, and chromosomal assignment of human DOC-2". Genomics 33 (2): 207–13. doi:10.1006/geno.1996.0185. PMID 8660969.
  2. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS (June 1998). "DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer". Oncogene 16 (18): 2381–7. doi:10.1038/sj.onc.1201769. PMID 9620555.
  3. "Entrez Gene: DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)".
  4. 1 2 Zhou J, Scholes J, Hsieh JT (February 2003). "Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer". J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID 12473651.
  5. 1 2 He J, Xu J, Xu XX, Hall RA (July 2003). "Cell cycle-dependent phosphorylation of Disabled-2 by cdc2". Oncogene 22 (29): 4524–30. doi:10.1038/sj.onc.1206767. PMID 12881709.
  6. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (April 2002). "The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2". J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID 11812785.
  7. 1 2 Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH (June 2003). "Regulation of the Wnt signaling pathway by disabled-2 (Dab2)". EMBO J. 22 (12): 3084–94. doi:10.1093/emboj/cdg286. PMC 162138. PMID 12805222.
  8. Oleinikov AV, Zhao J, Makker SP (May 2000). "Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin". Biochem. J. 347 Pt 3: 613–21. doi:10.1042/0264-6021:3470613. PMC 1220996. PMID 10769163.
  9. Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (May 2002). "Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton". Traffic 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID 11967127.
  10. Inoue A, Sato O, Homma K, Ikebe M (March 2002). "DOC-2/DAB2 is the binding partner of myosin VI". Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID 11906161.
  11. 1 2 Hocevar BA, Smine A, Xu XX, Howe PH (June 2001). "The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway". EMBO J. 20 (11): 2789–801. doi:10.1093/emboj/20.11.2789. PMC 125498. PMID 11387212.

Further reading


This article is issued from Wikipedia - version of the Saturday, December 26, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.